| Product Code: ETC9504368 | Publication Date: Sep 2024 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
Suriname import of adalimumab in 2024 saw a significant increase in concentration, with top exporting countries being Peru, Netherlands, USA, Brazil, and Germany. Despite a negative growth rate from 2023 to 2024, the compound annual growth rate (CAGR) for 2020-24 remained positive at 2.08%. This suggests a stable market performance over the years. The high concentration levels indicate a strong market presence for adalimumab imports in Suriname, emphasizing the importance of these key exporting countries in meeting the demand for this product.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Suriname Adalimumab Market Overview |
3.1 Suriname Country Macro Economic Indicators |
3.2 Suriname Adalimumab Market Revenues & Volume, 2021 & 2031F |
3.3 Suriname Adalimumab Market - Industry Life Cycle |
3.4 Suriname Adalimumab Market - Porter's Five Forces |
3.5 Suriname Adalimumab Market Revenues & Volume Share, By Drug class, 2021 & 2031F |
3.6 Suriname Adalimumab Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.7 Suriname Adalimumab Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.8 Suriname Adalimumab Market Revenues & Volume Share, By Dosage Strength, 2021 & 2031F |
3.9 Suriname Adalimumab Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.10 Suriname Adalimumab Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.11 Suriname Adalimumab Market Revenues & Volume Share, By Dosage Form, 2021 & 2031F |
4 Suriname Adalimumab Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Suriname Adalimumab Market Trends |
6 Suriname Adalimumab Market, By Types |
6.1 Suriname Adalimumab Market, By Drug class |
6.1.1 Overview and Analysis |
6.1.2 Suriname Adalimumab Market Revenues & Volume, By Drug class, 2021- 2031F |
6.1.3 Suriname Adalimumab Market Revenues & Volume, By Antirheumatics, 2021- 2031F |
6.1.4 Suriname Adalimumab Market Revenues & Volume, By TNF Alfa Inhibitors, 2021- 2031F |
6.1.5 Suriname Adalimumab Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Suriname Adalimumab Market, By Indication |
6.2.1 Overview and Analysis |
6.2.2 Suriname Adalimumab Market Revenues & Volume, By Rheumatoid Arthritis, 2021- 2031F |
6.2.3 Suriname Adalimumab Market Revenues & Volume, By Ankylosing Spondylitis, 2021- 2031F |
6.2.4 Suriname Adalimumab Market Revenues & Volume, By Chronic Plaque Psoriasis, 2021- 2031F |
6.2.5 Suriname Adalimumab Market Revenues & Volume, By Crohn's Disease, 2021- 2031F |
6.2.6 Suriname Adalimumab Market Revenues & Volume, By Ulcerative Colitis, 2021- 2031F |
6.2.7 Suriname Adalimumab Market Revenues & Volume, By Psoriatic Arthritis, 2021- 2031F |
6.2.8 Suriname Adalimumab Market Revenues & Volume, By Hidradenitis Suppurativa, 2021- 2031F |
6.2.9 Suriname Adalimumab Market Revenues & Volume, By Hidradenitis Suppurativa, 2021- 2031F |
6.3 Suriname Adalimumab Market, By Type |
6.3.1 Overview and Analysis |
6.3.2 Suriname Adalimumab Market Revenues & Volume, By Biologics, 2021- 2031F |
6.3.3 Suriname Adalimumab Market Revenues & Volume, By Biosimilars, 2021- 2031F |
6.4 Suriname Adalimumab Market, By Dosage Strength |
6.4.1 Overview and Analysis |
6.4.2 Suriname Adalimumab Market Revenues & Volume, By 40mg/0.4mlg, 2021- 2031F |
6.4.3 Suriname Adalimumab Market Revenues & Volume, By 80mg/0.8mlg, 2021- 2031F |
6.4.4 Suriname Adalimumab Market Revenues & Volume, By 20mg/0.2mlg, 2021- 2031F |
6.4.5 Suriname Adalimumab Market Revenues & Volume, By 10mg/0.1mlg, 2021- 2031F |
6.5 Suriname Adalimumab Market, By Drug Type |
6.5.1 Overview and Analysis |
6.5.2 Suriname Adalimumab Market Revenues & Volume, By Branded, 2021- 2031F |
6.5.3 Suriname Adalimumab Market Revenues & Volume, By Generics, 2021- 2031F |
6.6 Suriname Adalimumab Market, By Route of Administration |
6.6.1 Overview and Analysis |
6.6.2 Suriname Adalimumab Market Revenues & Volume, By Oral, 2021- 2031F |
6.6.3 Suriname Adalimumab Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.7 Suriname Adalimumab Market, By Dosage Form |
6.7.1 Overview and Analysis |
6.7.2 Suriname Adalimumab Market Revenues & Volume, By Injection, 2021- 2031F |
6.7.3 Suriname Adalimumab Market Revenues & Volume, By Solution, 2021- 2031F |
6.7.4 Suriname Adalimumab Market Revenues & Volume, By , 2021- 2031F |
7 Suriname Adalimumab Market Import-Export Trade Statistics |
7.1 Suriname Adalimumab Market Export to Major Countries |
7.2 Suriname Adalimumab Market Imports from Major Countries |
8 Suriname Adalimumab Market Key Performance Indicators |
9 Suriname Adalimumab Market - Opportunity Assessment |
9.1 Suriname Adalimumab Market Opportunity Assessment, By Drug class, 2021 & 2031F |
9.2 Suriname Adalimumab Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.3 Suriname Adalimumab Market Opportunity Assessment, By Type, 2021 & 2031F |
9.4 Suriname Adalimumab Market Opportunity Assessment, By Dosage Strength, 2021 & 2031F |
9.5 Suriname Adalimumab Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.6 Suriname Adalimumab Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.7 Suriname Adalimumab Market Opportunity Assessment, By Dosage Form, 2021 & 2031F |
10 Suriname Adalimumab Market - Competitive Landscape |
10.1 Suriname Adalimumab Market Revenue Share, By Companies, 2024 |
10.2 Suriname Adalimumab Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here